Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
December 19, 2023 16:05 ET
|
Compass Pathways
LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways appoints Teri Loxam as Chief Financial Officer
December 07, 2023 07:00 ET
|
Compass Pathways
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
December 06, 2023 16:00 ET
|
Compass Pathways
LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
Compass Pathways to participate in upcoming Evercore investor conference
November 24, 2023 08:00 ET
|
Compass Pathways
LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
November 15, 2023 04:00 ET
|
Compass Pathways
UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of study Research will take place in the UK, including at the newly opened...
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023 07:00 ET
|
COMPASS Pathways
Highlights: COMP360 Phase 3 pivotal program ongoing with expanding European clinical sitesSecured up to $285 million private placement financing with $125 million upfrontCash position at September 30,...
COMPASS Pathways announces CFO transition
October 26, 2023 08:00 ET
|
COMPASS Pathways
LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based...
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023
October 24, 2023 16:01 ET
|
COMPASS Pathways
LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways appoints Daphne Karydas to its Board of Directors
September 18, 2023 16:31 ET
|
COMPASS Pathways
LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
September 06, 2023 04:00 ET
|
COMPASS Pathways
LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental...